| ESSDS |
ESSDS |
92%
|
The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: Three Months Ended March 31, 2026 2025 ESSDS 41 % 42 % |
| MCK |
McKesson Corporation |
92%
|
The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: Three Months Ended March 31, 2026 2025 McKesson 12 % 11 % |
| MCK |
McKesson Corporation |
92%
|
Reciprocal relationship from MCK graph: Reciprocal relationship from JAZZ graph: Reciprocal relationship from MCK graph: Reciprocal relationship from JAZZ graph: The following table presents a summar… |
| AXSM |
Axsome Therapeutics, Inc. |
90%
|
Reciprocal relationship from AXSM graph: Reciprocal relationship from JAZZ graph: Reciprocal relationship from AXSM graph: Reciprocal relationship from JAZZ graph: Reciprocal relationship from AXSM g… |
| HOWL |
Werewolf Therapeutics, Inc. |
90%
|
Reciprocal relationship from HOWL graph: Jazz generally reimbursed us for the cost of such activities. |
| CARDINAL |
CARDINAL |
85%
|
Zepzelca, Rylaze, Vyxeos and Ziihera are sold to customers through subsidiary specialty distributors of McKesson, Cencora, and Cardinal |
| CENCORA |
CENCORA |
85%
|
Zepzelca, Rylaze, Vyxeos and Ziihera are sold to customers through subsidiary specialty distributors of McKesson, Cencora, and Cardinal |
| CNTA |
Centessa Pharmaceuticals plc |
72%
|
Reciprocal relationship from CNTA graph: Reciprocal relationship from JAZZ graph: Reciprocal relationship from CNTA graph: Reciprocal relationship from JAZZ graph: Reciprocal relationship from CNTA g… |
| CNTA |
Centessa Pharmaceuticals plc |
72%
|
own generic high-sodium oxybate product and determine the types of discounts or rebates they will offer parties that purchase or pay for the product. Generic competition often results in decreases in… |
| MRK |
Merck & Co., Inc. |
72%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from JAZZ graph: own generic high-sodium oxybate product and determine the types of discounts or rebates they will offer parties that p… |
| MRK |
Merck & Co., Inc. |
72%
|
own generic high-sodium oxybate product and determine the types of discounts or rebates they will offer parties that purchase or pay for the product. Generic competition often results in decreases in… |
| VOR |
Vor Biopharma Inc. |
72%
|
Reciprocal relationship from VOR graph: Vanflyta (quizartinib), Jazz Pharmaceuticals plc’s Vyxeos (daunorubicin and cytarabine), Novartis International AG’s Rydapt (midostaurin), Pfizer Inc.’s Mylota… |
| AZUR-MERGER-JAZZ-PHARMACEUTICALS-INC |
AZUR-MERGER-JAZZ-PHARMACEUTICALS-INC |
62%
|
92 216,565 184,000 Vyxeos 146,709 162,595 147,495 Modeyso 48,043 — — Ziihera 24,810 1,051 — Total Oncology 1,129,183 1,111,375 1,015,254 Other 14,172 11,471 13,846 Product sales, net 4,021,849 3,821,… |
| CHEMSPEC-USA-LLC |
CHEMSPEC-USA-LLC |
62%
|
Item 1. Siegfried supply sodium oxybate, the API of Xyrem, to Patheon and our Athlone facility. Although Siegfried has been our only supplier of sodium oxybate since 2012, we have the right to purcha… |
| CO-INC-EISAI-CO-LTD |
CO-INC-EISAI-CO-LTD |
62%
|
own generic high-sodium oxybate product and determine the types of discounts or rebates they will offer parties that purchase or pay for the product. Generic competition often results in decreases in… |
| DURBIN-PLC |
DURBIN-PLC |
62%
|
. Ziihera faces competition from generic chemotherapies, including cisplatin/gemcitabine rechallenge, and other HER2 directed therapies, including Enhertu and trastuzumab. An important part of our co… |
| FEDERAL-SUPPLY-SCHEDULE-GROUP |
FEDERAL-SUPPLY-SCHEDULE-GROUP |
62%
|
our major distributors in accordance with our inventory management agreements. Estimating these rebates is complex, in part due to the time delay between the date of sale and the actual settlement of… |
| HIKMA-AG |
HIKMA-AG |
62%
|
ion of AG versions of high-sodium oxybate and branded products, such as Avadel’s once-nightly dose, high-sodium oxybate branded product Lumryz, for treatment of cataplexy and/or EDS in adults with na… |
| JAZZ-PHARMACEUTICALS-INC |
JAZZ-PHARMACEUTICALS-INC |
62%
|
92 216,565 184,000 Vyxeos 146,709 162,595 147,495 Modeyso 48,043 — — Ziihera 24,810 1,051 — Total Oncology 1,129,183 1,111,375 1,015,254 Other 14,172 11,471 13,846 Product sales, net 4,021,849 3,821,… |
| LONZA-AG |
LONZA-AG |
62%
|
Item 1. Siegfried supply sodium oxybate, the API of Xyrem, to Patheon and our Athlone facility. Although Siegfried has been our only supplier of sodium oxybate since 2012, we have the right to purcha… |
| LONZA-SALES-AG |
LONZA-SALES-AG |
62%
|
Item 1. Siegfried supply sodium oxybate, the API of Xyrem, to Patheon and our Athlone facility. Although Siegfried has been our only supplier of sodium oxybate since 2012, we have the right to purcha… |
| SPRINGWORKS-THERAPEUTICS-INC |
SPRINGWORKS-THERAPEUTICS-INC |
62%
|
ended license agreement with PharmaMar, $375.0 million under the asset purchase and exclusive license agreement with SpringWorks Therapeutics, Inc., $260.0 million in connection with our acquisition … |
| XWPHARMA-LTD |
XWPHARMA-LTD |
62%
|
own generic high-sodium oxybate product and determine the types of discounts or rebates they will offer parties that purchase or pay for the product. Generic competition often results in decreases in… |
